A rating of 22 puts Crispr Therapeutics AG (CRSP) near the bottom of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 22 means it scores higher than 22% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 28, putting it above 28% of all stocks. Biotechnology is ranked 100 out of the 148 industries.
What do These Ratings Mean?
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is up 0.84% while the S&P 500 has fallen -0.56% as of 1:53 PM on Friday, Apr 30. CRSP is higher by $1.11 from the previous closing price of $131.88 on volume of 587,251 shares. Over the past year the S&P 500 is up 43.79% while CRSP is higher by 170.30%. CRSP lost -$5.62 per share the over the last 12 months.